All depends on market saturation too. Little, ineffective competition vs lots of effective competition. No generics vs uncountable generics.
One reason to use a BP to bring certain candidates to market.

We'll see how this pans out. I'm sure Leo will make good decisions. Non-binding agreement levels the playing field and brings competition into the scenario. If OM is the go to solution....